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Background. Interferon-free regimens to treat hepatitis C virus (HCV) genotype 1 are effective but costly. At this time, payers in 
the United States use strategies to control costs including (1) limiting treatment to those with advanced disease and (2) negotiating 
price discounts in exchange for exclusivity.
Methods. We used Monte Carlo simulation to investigate budgetary impact and cost effectiveness of these treatment policies and 
to identify strategies that balance access with cost control. Outcomes included nondiscounted 5-year payer cost per 10 000 HCV-
infected patients and incremental cost-effectiveness ratios.
Results. We found that the budgetary impact of HCV treatment is high, with 5-year undiscounted costs of $1.0 billion to 2.3 billion 
per 10 000 HCV-infected patients depending on regimen choices. Among noncirrhotic patients, using the least costly interferon-free 
regimen leads to the lowest payer costs with negligible difference in clinical outcomes, even when the lower cost regimen is less conven-
ient and/or effective. Among cirrhotic patients, more effective but costly regimens remain cost effective. Controlling costs by restricting 
treatment to those with fibrosis stage 2 or greater disease was cost ineffective for any patient type compared with treating all patients.
Conclusions. Treatment strategies using interferon-free therapies to treat all HCV-infected persons are cost effective, but short-
term cost is high. Among noncirrhotic patients, using the least costly interferon-free regimen, even if it is not single tablet or once 
daily, is the cost-control strategy that results in best outcomes. Restricting treatment to patients with more advanced disease often 
results in worse outcomes than treating all patients, and it is not preferred.
Keywords.  budget impact; HCV; treatment restriction.
New medications to treat hepatitis C virus (HCV) are costly, 
with wholesale acquisition costs exceeding $1000/day in the 
United States [1]. Several recent cost-effectiveness analyses 
concur that even at such high prices, all oral sofosbuvir-based 
regimens to treat HCV genotype 1 (GT1) provide good value 
compared with the previous standard of care [2–6]. Given that 
there are 2–3 million HCV-infected people in the United States 
[7], however, the budget impact of providing new HCV treat-
ments to all who need them could exceed the healthcare sys-
tem’s ability to pay, despite attractive cost-effectiveness ratios 
[2–4]. As multiple interferon-free regimens enter the market, 
payers negotiate with pharmaceutical manufacturers cover-
ing 1 exclusive interferon-free treatment regimen in exchange 
for substantial price discounts, potentially trading efficacy for 
lower cost [8]. Many insurers further limit access to new HCV 
therapies by prioritizing patients with higher degrees of liver 
fibrosis for treatment, although there is no consensus on this 
threshold with thresholds ranging from fibrosis stage 2 (F2) to 
F4 [9]. Because these restrictions are recent inventions, data are 
needed to inform decision making and to shed light on the rel-
ative costs and benefits of different approaches to controlling 
HCV treatment costs.
In this environment—where alternative treatment options 
are both highly efficacious and costly—it is particularly impor-
tant to understand the budgetary impact and economic value 
of new treatments as well as to identify approaches to expand 
access while controlling cost. We used the Hepatitis C Cost-
Effectiveness (HEP-CE) Model [10, 11] to consider the policy 
questions that payers currently face when considering coverage 
of high-cost HCV medications in the competitive US market 
including the following: (1) how much to budget for every 
10 000 HCV-infected patients within a jurisdiction or health 
plan, (2) how to make cost-effective trade-offs between efficacy 
and cost, and (3) whether to contain costs by limiting access to 
only those with F2 or greater.
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METHODS
Overview
The HEP-CE Model is a Monte Carlo lifetime simulation of 
HCV infection, screening, and treatment, summarized briefly 
below and in greater detail in the Supplementary Materials 
and published literature [10, 11]. We constructed the model 
and performed analyses using TreeAge Pro software (TreeAge 
Software, Inc., Williamstown, MA).
We assumed the health system perspective on treatment costs 
for HCV GT1 in patients who are engaged in care and prepared 
to initiate HCV therapy. We considered distinct patient types 
defined by GT1 subtype (1a vs 1b), fibrosis stage (noncirrhotic 
vs cirrhotic), treatment history (naive vs experienced), and rib-
onucleic acid (RNA) level for treatment-naive, noncirrhotic 
patients (<6 million copies vs ≥6 million copies) (Table  1). 
Each of these patient types was associated with a distinct menu 
of treatment options (Table 1) and related sustained virologic 
response (SVR). We did not evaluate treatment of decompen-
sated cirrhosis.
We used the model to simulate clinical outcomes and costs 
for hypothetical cohorts of 1 million patients for each patient 
type and treatment strategy. Outcomes included the following: 
quality-adjusted life years (QALYs) and lifetime medical costs, 
each discounted at 3% annually [12], and the 5-year, undis-
counted budgetary impact per 10 000 HCV-infected patients 
[13]. To estimate the 5-year budget impact, we ran the model 
for 5 simulated years to estimate mean undiscounted cost per 
patient. We then multiplied that 5-year mean cost by 10 000 
to estimate the total budget impact. We chose a 5-year hori-
zon because that is a time period of relevance to payers [13]. 
We express budget impact in terms of cost/10 000 because 
that quantity can be scaled up or down by payers to estimate 
budgetary impact for their specific populations. We calculated 
the incremental cost-effectiveness ratio (ICER) for each strat-
egy by dividing the additional lifetime cost by the additional 
QALYs gained compared with the next less expensive strat-
egy [12]. We deemed regimens that provided lower QALYs at 
higher total cost than an alternative, as well as regimens that 
provided fewer QALYs at a higher cost per QALY gained, to be 
inefficient (dominated), and we excluded them from the final 
comparisons [12].
We next modeled a scenario in which noncirrhotic patients 
could be treated for HCV only when they reached METAVIR 
F2 or greater (F2+ only). Because of the large potential num-
ber of strategies when considering all regimens and treatment 
restrictions a priori, we developed an approach to incorporating 
the “treat F2+ only” approach. First, we identified the preferred 
interferon-free regimen for a given patient type assuming the 
“treat-all” approach. We then considered the “F2+ only” strategy 
only for the preferred treatment regimen. In addition, because 
the quality of life (QoL) of patients with early stage HCV infec-
tion is uncertain, and this value can affect the cost effectiveness 
of early HCV therapy, we included a scenario in which patients 
with early HCV had a much higher QoL than they did in the 
base case analysis.
Finally, we performed a series of sensitivity analyses in which 
we varied the efficacy and cost of one interferon-free regimen, 
while holding constant the efficacy and cost of all others. We 
report the relationships between relative efficacy, cost, and cost 
effectiveness using 2-way sensitivity analysis graphs [12].
We performed extensive deterministic and probabilistic 
sensitivity analyses. A  priori parameters of interest included 
treatment efficacy, treatment cost, fibrosis staging test charac-
teristics (sensitivity and specificity of correctly identifying a 
given stage), QoL with early HCV, mean age of the population, 
and QoL after SVR. We performed 2-way sensitivity analyses in 
which we considered various combinations of rates of fibrosis 
progression and QoL with early disease. We summarize sensi-
tivity analysis results using one-way graphs and cost-effective-
ness acceptability curves.
Table 1. Treatment Strategies Considered in a Cost-Effectiveness Analysis of Therapies for HCV Genotype 1 Infection
Treatment History Noncirrhotic Cirrhotic
Treatment-naive 48 weeks pegylated-interferon/ribavirin
24 weeks simeprevir/pegylated-interferon/ribavirin
12 weeks sofosbuvir/pegylated-interferon/ribavirin
8 weeks sofosbuvir/ledipasvir (HCV RNA <6 million)
12 weeks sofosbuvir/ledipasvir (HCV RNA ≥6 million)
12 weeks paritaprevir-ritonavir/ombitasvir/dasabuvir 
/(ribavirin)a
12 weeks daclatasvir/sofosbuvir
48 weeks pegylated-interferon/ribavirin
24 weeks simeprevir/pegylated-interferon/ribavirin
12 weeks sofosbuvir/pegylated-interferon/ribavirin
12 weeks sofosbuvir/ledipasvir
12 weeks paritaprevir-ritonavir/ombitasvir/dasabuvir/ribavirin
24 weeks daclatasvir/sofosbuvir
Treatment-experienced 12 weeks sofosbuvir/pegylated-interferon/ribavirin
12 weeks simeprevir/sofosbuvir
12 weeks sofosbuvir/ledipasvir
24 weeks sofosbuvir/ledipasvir
12 weeks paritaprevir-ritonavir/ombitasvir/dasabuvir/ribavirin
12 weeks daclatasvir/sofosbuvir
12 weeks sofosbuvir/pegylated-interferon/ribavirin
12 weeks simeprevir/sofosbuvir
12 weeks sofosbuvir/ledipasvir/ribavirin
24 weeks sofosbuvir/ledipasvir
12 to 24 weeks paritaprevir-ritonavir/ombitasvir/dasabuvir/ribavirinb
24 weeks daclatasvir/sofosbuvir/ribavirin
Abbreviations: HCV, hepatitis C virus; RNA, ribonucleic acid.
aRibavirin is included for genotype 1a and not for 1b patients.
bTwelve weeks for 1b patients, 24 weeks regimen for genotype 1a patients.
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Model Structure
Hepatitis C Virus Disease Progression
The simulation includes 3 stages of liver disease: mild to mod-
erate fibrosis, cirrhosis, and decompensated cirrhosis; the rate 
of progression varies among simulated patients, and the model 
operationalizes this variation by randomly drawing the time 
from the date of HCV infection to that of developing cirrhosis 
so that at model start an individual’s fibrosis stage is a func-
tion of their age, age of infection, and fibrosis progression (see 
Supplementary Appendix for details). For F2+ only strategies, 
we considered simulated patients to have reached F2 disease 
when they had accrued 50% of their total time from HCV infec-
tion to cirrhosis.
At every disease stage, HCV infection is associated with 
higher costs and lower QoL compared with HCV-uninfected 
individuals [14–16] (Table  2). When patients reach cirrho-
sis, they are subject to HCV-attributable mortality. The rate of 
HCV-attributable mortality further increases when patients 
reach decompensated cirrhosis, reflecting both the increasing 
risks posed by advanced liver disease such as hepatocellular 
carcinoma and the elevated mortality risk of extrahepatic con-
ditions such as esophageal varices [17].
Competing Causes of Death
In every month, individuals in the model are exposed to age- 
and sex-stratified risk of death from causes other than HCV 
[18]. Because this analysis focuses specifically on HCV-infected 
patients who are engaged in medical care and ready to initiate 
HCV therapy, we assume that competing risks are similar to 
those of the general population, and we explore that assumption 
in sensitivity analyses.
Hepatitis C Virus Treatment Simulation
The probability of attaining SVR to treatment is specific to 
regimen and patient type, and it is a function of the proba-
bilities of withdrawing from treatment for nonadherence or 
toxicity and achieving SVR conditional on completing treat-
ment (Table 2). Patients taking pegylated-interferon/ribavirin 
or pegylated-interferon/ribavirin/simeprevir who have inad-
equate virologic response at treatment week 12 discontinue 
treatment [19–21]. There are no early stopping criteria for 
any other regimen [22–25]. We did not consider patients with 
previous exposure to HCV polymerase inhibitors or NS5A 
inhibitors.
In F2+ only strategies, noncirrhotic patients are eligible to start 
therapy only when their fibrosis is clinically identified. We assume 
annual fibrosis staging with test characteristics representative of 
the mean sensitivity and specificity reported for the Fibroscan 
and Fibrosis-4 tests (Table 2) to identify moderate fibrosis [26]. 
Thus, some early stage patients receive therapy, whereas other 
advanced patients are incorrectly delayed. We conducted a sensi-
tivity analysis in which we assumed perfect staging.
We developed efficacy parameters using data from multiple 
clinical trials [19–25, 27–32]. We used a Bayesian approach 
to develop probability density functions around each effi-
cacy parameter value. The expected value of each distribution 
matched the data reported from clinical trials, whereas the var-
iance reflected uncertainty surrounding the data based on sam-
ple size (Supplemental Tables 1 and 2).
Costs
We denominate costs in 2014 US dollars, and when necessary 
input costs were inflated to 2014 dollars using the consumer 
price index. In each simulation month, individuals accrue non-
HCV-related costs based on age and sex (Table 2) [33]. Monthly 
costs related to HCV increase with advancing disease due to the 
increasing risk of liver disease sequelae such as hepatocellular 
carcinoma and liver transplantation as well as extrahepatic man-
ifestations of HCV [34]. Because HCV-related costs are variable 
across patients, we estimate probability density functions around 
these costs using the gamma distribution. We then assign each 
simulated patient a disease stage-specific monthly HCV-related 
cost by random draw from those distributions (Table 2).
The costs of HCV therapy include costs of HCV medications, 
clinic visits, laboratory tests, and on-treatment toxicity man-
agement (Table 2, Supplemental Table 3). We assume that the 
cost of HCV therapies includes the medication discount avail-
able to public payers such as Medicaid plans, which we model 
as the average wholesale price (AWP) less 23% [1, 35]. Due to 
the rapid evolution in the HCV treatment market, competitive 
negotiation, and price discounts, we performed extensive sensi-
tivity analyses on medication cost.
Quality-of-Life
Quality-of-life reflects the combination of 3 utility functions: (1) 
utility related to non-HCV comorbidities, which is a function of 
age [36]; 2) HCV-specific utility, which is a function of fibrosis 
stage [14–16]; and (3) treatment-related utility, reflecting lower 
QoL on interferon-containing regimens as well as major toxicity 
events on treatment in all regimens [37–39]. In addition, because 
the QoL with early stage HCV is uncertain and has a potentially 
large impact on the cost-effectiveness of early HCV therapy, we 
included a scenario in which early stage HCV is assigned a QoL 
weight of 0.95 [6, 14, 40]. We assumed that effects of each of these 
utility functions on total utility are independent and proportional.
Benefits of Sustained Virologic Response 
When patients attain SVR, fibrosis progression halts, HCV-
attributable costs are reduced to 50% of an individual’s dis-
ease stage-specific cost before initiating therapy [34], and 
QoL reverts to that of HCV-uninfected individuals of the 
same age and sex [37]. In individuals who were cirrhotic 
before attaining SVR, liver-related mortality decreases by 
94% [41].
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Table 2. Model Inputs for a Cost-Effectiveness Analysis of Strategies for Cost Containment in Provision of Interferon-Free Therapy for HCV Genotype 1
Variable Base Case Value Range Evaluated in Sensitivity Analysesa Source(s)
Cohort Characteristics
 Mean age treatment-naive (SD), years 52 (14) 42 (14)–62 (14) [23]
 Mean age treatment-experienced (SD), years 56 (14) 46 (14)–66 (14) [22]
 Proportion male (treatment-naive) 0.59 0–1 [23]
 Proportion male (treatment-experienced) 0.68 0–1 [22]
 Average age at HCV infection, years 26 16–36 [34]
HCV Disease Progression
 Median time to cirrhosis from time of HCV infection, years 25 10–40 [48, 49]
 Median time to first liver-related event after developing cirrhosis, years 11 6–19 [17]
 Liver-related mortality with compensated cirrhosis, deaths/100 PYs 1.39 0.96–1.82 [17]
 Liver-related mortality with decompensated cirrhosis, deaths/100 PYs 12.00 8.28–15.72 [17]
 Reduction in liver-mortality after SVR, %b 94 81–98 [41]
HCV Therapy Efficacy, Treatment-Naivec
SVR probabilities for 48 weeks pegylated-interferon/ribavirin [19]
 Genotype 1 without cirrhosis 0.44 0.44 (0.02)
 Genotype 1 with cirrhosis 0.24 0.23 (0.04)
SVR probabilities for 24 weeks pegylated-interferon/ribavirin/simeprevir [20, 21]
 Genotype 1a without cirrhosis 0.78 0.77 (0.03)
 Genotype 1a with cirrhosis 0.55 0.53 (0.10)
 Genotype 1b without cirrhosis 0.91 0.89 (0.02)
 Genotype 1b with cirrhosis 0.65 0.63 (0.10)
SVR probabilities for 12 weeks pegylated-interferon/ribavirin/sofosbuvir [32]
 Genotype 1 without cirrhosis 0.92 0.92 (0.02)
 Genotype 1 with cirrhosis 0.80 0.79 (0.05)
SVR probability for 8 weeks sofosbuvir/ledipasvir [28, 50]
 Genotype 1 without cirrhosis 0.97 0.96 (0.02)
SVR probability for 12 weeks sofosbuvir/ledipasvir [28, 50]
 Genotype 1 without cirrhosis 0.96 0.96 (0.02)
 Genotype 1 with cirrhosis 0.97 0.95 (0.04)
SVR probability for 12 weeks paritaprevir-ritonavir/ombitasvir/dasabuvir ± ribavirin [29, 31]
 Genotype 1a without cirrhosis (with ribavirin) 0.97 0.97 (0.02)
 Genotype 1a with cirrhosis (with ribavirin) 0.92 0.91 (0.04)
 Genotype 1b without cirrhosis (without ribavirin) 0.99 0.98 (0.01)
 Genotype 1b with cirrhosis (with ribavirin) 0.99 0.97 (0.03)
SVR probability for 12 or 24 weeks of daclatasvir/sofosbuvir
 Genotype 1 without cirrhosis (12 weeks) 0.99 0.99 (0.01) [25]
 Genotype 1 with cirrhosis (24 weeks) 0.99 0.99 (0.01) [27]
HCV Therapy Efficacy, Treatment-Experiencedc
SVR probability for 12 weeks pegylated-interferon/ribavirin/sofosbuvir [32]
 Genotype 1 without cirrhosis 0.92 0.92 (0.02)
 Genotype 1 with cirrhosis 0.80 0.78 (0.06)
SVR probability for 12 or 24 weeks of sofosbuvir/ledipasvir [22]
 Genotype 1 without cirrhosis (12 weeks) 0.95 0.95 (0.02)
 Genotype 1 with cirrhosis (24 weeks) 0.99 0.97 (0.02)
SVR probabilities for 12 or 24 weeks paritaprevir-ritonavir/ombitasvir/dasabuvir/ribavirin [30, 31]
 Genotype 1a without cirrhosis (12 weeks) 0.96 0.96 (0.02)
 Genotype 1a with cirrhosis (24 weeks) 0.95 0.94 (0.02)
 Genotype 1b without cirrhosis (12 weeks) 0.97 0.96 (0.01)
 Genotype 1b with cirrhosis (12 weeks) 0.97 0.96 (0.01)
SVR probability for 12 weeks sofosbuvir/simeprevir [24]
 Genotype 1a without cirrhosis 0.90 0.88 (0.10)
 Genotype 1a with cirrhosis 0.91 0.89 (0.08)
 Genotype 1b without cirrhosis 0.99 0.99 (0.00)
 Genotype 1b with cirrhosis 0.99 0.97 (0.01)
SVR probability for 12 weeks of sofosbuvir/ledipasvir/ribavirin
 Genotype 1 with cirrhosis 0.96 0.94 (0.02) [51]
SVR probability for 12 or 24 weeks of daclatasvir/sofosbuvir ± ribavirin
 Genotype 1 without cirrhosis (12 weeks without ribavirin) 0.99 0.99 (0.01) [25]
 Genotype 1 with cirrhosis (24 weeks with ribavirin) 0.98 0.97 (0.01) [27]
Fibrosis staging (for F2+ only strategy) [26]
 FibroScan sensitivity to detect F2 or greater 0.48 0.48–1
 FibroScan specificity to detect F2 or greater 0.93 0.93–1
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Variable Base Case Value Range Evaluated in Sensitivity Analysesa Source(s)
Costs
Non-HCV-related medical costs, $ per month
 Background medical costs (without HCV) 
d $140–$1050 $70–$1575 [33]
HCV-related medical costs, $ per month
 No cirrhosis (SD) $245 ($60) $185 ($45)–$305 ($75) [34]
 Mild to moderate cirrhosis (SD) $440 ($125) $315 ($90)–$550 ($150) [34]
 Decompensated cirrhosis (SD) $830 ($215) $620 ($160)–$1050 ($260) [34]
 Costs multiplier after achieving SVR 0.50 0–0.70 [34]
 HCV Therapy Costs, $ per 4 Weeks
 Provider visit costse $120 $60–180 [52, 53]
 Pegylated-interferonf $720 $370–$1200 [1]
 Ribaviring $1200 $560–$1700 [1]
 Sofosbuvir $26 500 $13 000–$40 000 [1]
 Sofosbuvir/ledipasvir $29 000 $15 000–$43 000 [1]
 Simeprevir $21 000 $11 000–$32 000 [1]
 Paritaprevir-ritonavir/ombitasvir/dasabuvir $26 000 $13 000–$39 000 [1]
 Daclatasvir $19 300 $9500–$28 500 [1]
 Filgrastimh $2800 $1500–$5100 [1]
Complete HCV therapy costs, $ [1, 52, 53]
 Pegylated-interferon/ribavirin 48 weeks $52 600 $26 000–$79 500
 Pegylated-interferon/ribavirin/simeprevir 24 weeks $75 000 $37 500–$113 000
 Pegylated-interferon/ribavirin/sofosbuvir 12 weeks $91 000 $45 500–$137 000
 Sofosbuvir/ledipasvir 8 weeks $58 200 $29 000–$88 200
 Sofosbuvir/ledipasvir 12 weeks $87 300 $47 300–$107 300
 Sofosbuvir/ledipasvir 24 weeks $175 000 $115 000–$215 000
 Sofosbuvir/ledipasvir/ribavirin 12 weeks $90 600 $31 000–$112 000
 Paritaprevir-ritonavir/ombitasvir/dasabuvir 12 weeks $77 000 $23 000–$97 000
 Paritaprevir-ritonavir/ombitasvir/dasabuvir/ribavirin 12 weeks $80 300 $30 000–$100 300
 Paritaprevir-ritonavir/ombitasvir/dasabuvir/ribavirin 24 weeks $161 000 $101 000–$201 000
 Sofosbuvir/simeprevir 12 weeks $139 000 $69 500–$209 000
 Daclatasvir/sofosbuvir 12 weeks $137 000 $68 500–$206 000
 Daclatasvir/sofosbuvir 24 weeks $274 000 $137 000–$411 000
 Daclatasvir/sofosbuvir/ribavirin 24 weeks $280 000 $140 000–$420 000
One-time costs, $
 Managing treatment-ending toxicity on interferon-containing therapy $465–$877 $360–$1200 [1, 19, 20, 32, 52–55]
 Managing treatment-ending toxicity on interferon-free therapy $241 $100–$610 [29, 52–55]
Quality of life 
i
 After achieving SVR 0.74–0.92 0.60–1 [37]
With HCV Infection
 No-to-moderate fibrosis 0.89 0.75–1 [14–16]
 Cirrhosis 0.62 0.55–0.75 [14, 15]
 Decompensated cirrhosis 0.48 0.40–0.60 [14, 15]
 Receiving interferon-containing therapy j 0.88 0.50–0.96 [37, 38]
 Receiving interferon-free therapy j 0.99 0.95–1 [38]
 Major toxicity decrement k 0.16 0.09–0.25 [39]
Abbreviations: F2, fibrosis stage 2; HCV, hepatitis C virus; PYs, person-years; SD, standard deviation; SVR, sustained virologic response. 
(NOTE: All costs are in 2014 US dollars and discounted at an annual rate of 3%.).
a Sensitivity analyses on HCV therapy efficacy were probabilistic as opposed to deterministic (see Methods). The table provides the approximate mean and SD of the beta distribution developed to reflect uncertainty in efficacy 
estimates.
b Because HCV-attributable mortality is only applied in the model once individuals are cirrhotic, this probability is applied only to individuals who had cirrhosis before initiating treatment and subsequently attained SVR.
c Efficacy estimates for patient subgroups (eg, genotype 1b treatment-naive with cirrhosis) are informed by clinical trials.
dCosts varied as a function of age and sex.
eCost in first month is higher ($750).
f 15% of patients on pegylated-interferon/ribavirin and sofosbuvir/pegylated-interferon/ribavirin therapy receive a reduced weekly dose of 135 mcg due to nontreatment-ending neutropenia (absolute neutrophil count <750/mL 
but ≥500/mL) in addition to twice weekly filgrastim 300 mcg [32].
g 26% of patients on pegylated-interferon/ribavirin, 20% of patients pegylated-interferon/ribavirin/ sofosbuvir therapy, 23% of patients on pegylated-interferon/ribavirin/simeprevir, and 6% of patients on paritaprevir-ritonavir/
ombitasvir/dasabuvir/ribavirin therapy were treated with a reduced dose of daily ribavirin in response to nontreatment-ending anemia (grade 3–4 adverse event of hemoglobin <10 g/dL) [19–21, 29].
h The cost of a nurse visit ($20.40) is also included for anemia management [52].
i Utility without HCV infection is a function of age. To estimate utility in a given month, the model uses a multiplicative assumption to combine HCV-related utility with age- and sex-stratified utility without HCV. For 
example, the utility estimate without HCV infection for a 55-year-old is 0.84. The estimated utility of living with compensated cirrhosis is 0.62. A 55-year-old with compensated cirrhosis would have a modeled utility of 
0.84 × 0.62 = 0.52.
j This utility weight was multiplied by an individual’s health state utility during the months that the individual received HCV therapy without major toxicity.
k This utility loss was subtracted from a patient’s health state utility during the month of a major toxicity event.
Table 2. Continued
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RESULTS
Cost Control by Deferring Treatment Until Fibrosis Stage 2 (F2± Only)
Treating all noncirrhotic patients with an interferon-free reg-
imen regardless of disease stage resulted in a nondiscounted 
5-year payer cost in the range of $1.02 billion to $2.14 billion per 
10 000 patients treated, quality adjusted life expectancy of 14.4 to 
14.7 QALY per patient, and a discounted lifetime medical cost of 
$227 000 to $329 000 per patient. Strategies that limited access to 
patients with F2 or greater fibrosis had lower 5-year total cost, but 
strategies that treated all patients resulted in better quality-ad-
justed life expectancy and provided good value for money.
In all patient types, treat all strategies had economically attractive 
ICERs according to conventional benchmarks (ICER <$100 000/
QALY), and in many patient types treat-all provided better out-
comes than F2+ only at a lower cost per QALY gained (Tables 3 and 
4). These findings were robust in all age groups (mean age 42 and 
mean age 62) and with various assumptions about rates of fibrosis 
progression, mortality (including doubling the risk of death from 
non-HCV mortality), cost, and rates of HCV reinfection after 
SVR (Supplemental Tables 4–15) as well as QoL (Supplemental 
Figure 1). When we assumed high QoL with noncirrhotic HCV 
infection (0.95), the qualitative conclusions did not change 
(Supplemental Table 16). In probabilistic sensitivity analyses, F2+ 
only was almost never preferred for any patient type (Figure 1).
The F2+ only approach was not preferred for several reasons. 
First, patients had lower QoL as liver fibrosis advances, and 
therefore they lost QALYs while waiting for therapy. In sensi-
tivity analyses, treat-all strategies were preferred unless the util-
ity weight of early stage HCV infection was >0.97 (base case 
0.89) (Supplemental Figure 1). Second, most patients eventually 
reached F2 and were ultimately treated for HCV. For example, 
among GT1a, treatment-naive, noncirrhotic patients, 92% were 
ultimately treated for HCV. In sensitivity analysis with slower 
fibrosis progression rates (median time to cirrhosis = 40 years), 
treat all remained preferred. Only when the discount rate was 
greater than 10% (base case 3% in accordance with current 
guidelines for economic analysis) did F2+ only strategies begin 
to have ICERs <$100 000/QALY. Third, noninvasive fibrosis 
staging modalities are imperfect [26], and some patients with 
advanced fibrosis were inappropriately deferred. Eliminating 
uncertainty in fibrosis staging improved outcomes and decreased 
the ICER of F2+ only, but the ICER of treat all remained attrac-
tive (<$100 000/QALY) (Supplemental Table 17).
Cost Control by Negotiating Price Discounts and Requiring Use of 
Preferred Drugs
Noncirrhotic Patients
Among noncirrhotic patients, genotypes 1a and 1b, the choice 
of which interferon-free regimen to use depended on regimen 
cost. For example, among GT 1a and 1b treatment-naive, noncir-
rhotic patients with HCV RNA <6 million copies/mL, for whom 
sofosbuvir/ledipasvir is an 8-week regimen, sofosbuvir/ledipasvir 
dominated interferon-containing regimens, and the ICER of 
sofosbuvir/ledipasvir compared with “no treatment” was $21 700/
QALY. In such patients, paritaprevir/ritonavir/ombitasvir/dasa-
buvir ± ribavirin was estimated to be slightly more effective than 
sofosbuvir/ledipasvir (97%–98% SVR vs 96% SVR), but because 
the 12-week paritaprevir/ritonavir/ombitasvir/dasabuvir ± ribavi-
rin treatment course greatly increased cost relative to 8 weeks of 
sofosbuvir/ledipasvir, the ICER of paritaprevir/ritonavir/ombi-
tasvir/dasabuvir ± ribavirin among treatment-naive patients with 
RNA <6 million copies/mL was more than $600 000/QALY gained. 
Likewise, in GT1a and GT1b noncirrhotic patients, sofosbuvir/
daclatasvir had the highest modeled treatment efficacy, but because 
of its high cost, it was never preferred for noncirrhotic patients.
In two-way sensitivity analyses among noncirrhotic patients, 
each percentage point improvement in interferon-free regi-
men efficacy could support an additional cost of only $875 per 
month of treatment ($2625 for a 12-week course). Larger cost 
increases resulted in the more effective regimen having an ICER 
>$100 000/QALY gained compared with the less effective regi-
men (Figure 2).
In probabilistic sensitivity analyses, interferon-free therapy 
had an ICER <$100 000/QALY in >99% of simulations, with the 
least costly interferon-free regimen always preferred when the 
threshold for willingness to pay for each year of healthy life was 
$100 000/QALY gained (Supplemental Figure 2).
Cirrhotic Patients
Among cirrhotic patients, genotype 1a and 1b, regimen efficacy 
played a larger role in determining the choice of which interfer-
on-free regimen was cost effective. In two-way sensitivity analy-
ses, each additional percentage point of regimen efficacy could be 
associated with up to a $2400 increase in monthly regimen cost 
($7200 for a 12-week treatment course) for the more effective 
regimen to remain cost effective with an ICER <$100 000/QALY 
(Figure 1). Even among cirrhotic patients, however, very small dif-
ferences in treatment efficacy did not provide adequate improve-
ment in outcomes to justify the very high cost of some regimens. 
For example, sofosbuvir/daclatasvir, which was the most effective 
regimen for many cirrhotic patients, had a very high ICER due to 
its high cost. In probabilistic sensitivity analyses, interferon-free 
therapy had an ICER <$100 000/QALY in >99% of simulations, 
and the more effective interferon-free regimen was preferred in 
>75% of simulations (Supplemental Figure 3).
DISCUSSION
Our analysis demonstrates that interferon-free therapies to 
treat HCV GT1 provide good value for the resources required 
to use them broadly in the United States, but they are costly for 
payers. Cost-control strategies in which noncirrhotic patients 
are eligible for treatment only when they reach F2 or greater 
fibrosis do limit cost; however, treating all patients regardless of 
fibrosis stage results in longer quality-adjusted life-expectancy 
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Table 3. Cost Effectiveness of Treatment for Hepatitis C Virus Infection Among Genotype 1a and 1b Noncirrhotic Patients Assuming Both “Treat All” and 
“F2+ Only” Approaches
Treatment Strategy Cost, $
Incremental 
Cost, $ QALYs
Incremental 
QALYs
ICER,  
$/QALY SVR, %
Nondiscounted  
Cost/10 000  
Patients, Billion $
Genotype 1a, Treatment-Naive, RNA <6 Million
 No treatment 165 000 - 11.5 - - - 0.37
 PEG/RBV 48 weeks 206 000 40 800 12.8 1.3 Dominateda 43.4 0.84
 SOF/LDV 8 weeks treating only F2+ 227 000 61 900 14.4 2.9 21 700 88.6 1.02
 PEG/RBV/SMV 24 weeks 231 000 3800 13.9 −0.4 Dominateda 77.3 1.13
 SOF/LDV 8 weeks 233 000 5900 14.6 0.3 22 300 96.2 1.17
 PTV/r/OBV/DSV/RBV 12 weeks 252 000 19 000 14.7 0.0 610 000 97.6 1.36
 PEG/RBV/SOF 12 weeks 266 000 14 100 14.5 −0.2 Dominateda 92.4 1.50
 DCV/SOF 12 weeks 329 000 76 500 14.7 0.1 1 520 000 99.1 2.14
Genotype 1a, Treatment-Naive, RNA ≥6 Million
 No treatment 165 000 - 11.5 - - - 0.37
 PEG/RBV 48 weeks 206 000 41 000 12.8 1.3 Dominateda 43.6 0.84
 PEG/RBV/SMV 24 weeks 231 000 24 700 13.9 1.1 Dominateda 77.2 1.13
 PTV/r/OBV/DSV/RBV 12 weeks treating only F2+ 243 000 77 900 14.4 2.9 27 100 89.8 1.17
 PTV/r/OBV/DSV/RBV 12 weeks 252 000 8900 14.7 0.3 32 600 97.5 1.36
 SOF/LDV 12 weeks 261 000 8800 14.6 0.0 Dominateda 96.2 1.45
 PEG/RBV/SOF 12 weeks 266 000 14 100 14.5 −0.2 Dominateda 92.3 1.50
 DCV/SOF 12 weeks 329 000 76 500 14.7 0.1 1 400 000 99.1 2.14
Genotype 1a, Treatment-Experienced
 No treatment 156 000 - 11.5 - - - 0.39
 PTV/r/OBV/DSV/RBV 12 weeks treating only F2+ 236 000 80 400 13.9 2.3 Dominateda 85.6 1.21
 PTV/r/OBV/DSV/RBV 12 weeks 245 000 89 300 14.0 0.2 28 300 95.6 1.39
 SOF/LDV 12 weeks 255 000 9500 14.0 0.0 Dominateda 94.7 1.48
 PEG/RBV/SOF 12 weeks 258 000 13 000 13.9 −0.1 Dominateda 92.3 1.52
 DCV/SOF 12 weeks 320 000 74 600 14.1 0.1 700 000 98.9 2.15
 SMV/SOF 12 weeks 321 000 1500 13.9 −0.3 Dominateda 88.4 2.15
Genotype 1b, Treatment-Naive, RNA <6 Million
 No treatment 165 000 - 11.5 - - - 0.37
 PEG/RBV 48 weeks 206 000 40 700 12.8 1.3 Dominateda 43.5 0.84
 SOF/LDV 8 weeks treating only F2+ 227 000 61 900 14.4 2.9 21 700 88.5 1.02
 PEG/RBV/SMV 24 weeks 232 000 5400 14.3 −0.1 Dominateda 87.9 1.16
 SOF/LDV 8 weeks 233 000 5900 14.6 0.3 22 700 96.1 1.17
 PTV/r/OBV/DSV 12 weeks 248 000 14 900 14.7 0.1 182 000 98.4 1.32
 PEG/RBV/SOF 12 weeks 266 000 18 400 14.5 −0.2 Dominateda 92.4 1.50
 DCV/SOF 12 weeks 329 000 80 800 14.7 0.0 4 190 000 99.1 2.14
Genotype 1b, Treatment-Naive, RNA ≥6 Million
 No treatment 165 000 - 11.5 - - - 0.37
 PEG/RBV 48 weeks 206 000 41 100 12.8 1.3 Dominateda 43.5 0.84
 PEG/RBV/SMV 24 weeks 232 000 67 200 14.3 2.8 24 400 87.8 1.16
 PTV/r/OBV/DSV 12 weeks treating only F2+ 239 000 6800 14.4 0.2 Dominateda 90.7 1.13
 PTV/r/OBV/DSV/RBV 12 weeks 248 000 15 200 14.7 0.4 35 500 98.4 1.32
 SOF/LDV 12 weeks 261 000 13 200 14.6 −0.1 Dominateda 96.3 1.45
 PEG/RBV/SOF 12 weeks 266 000 18 400 14.5 −0.2 Dominateda 92.4 1.50
 DCV/SOF 12 weeks 329 000 80 800 14.7 0.0 4 470 000 99.1 2.14
Genotype 1b, Treatment-Experienced
 No treatment 156 000 - 10.8 - - - 0.39
 PTV/r/OBV/DSV/RBV 12 weeks treating only F2+ 236 000 80 200 13.7 2.8 Dominateda 86.1 1.21
 PTV/r/OBV/DSV/RBV 12 weeks 245 000 89 100 14.0 3.2 28 000 96.2 1.39
 SOF/LDV 12 weeks 255 000 9800 14.0 0.0 Dominateda 94.7 1.48
 PEG/RBV/SOF 12 weeks 258 000 13 200 13.9 −0.2 Dominateda 92.3 1.52
 DCV/SOF 12 weeks 320 000 75 000 14.1 0.1 814 000 99.0 2.15
 SMV/SOF 12 weeks 324 000 3700 14.1 0.0 Dominateda 98.7 2.19
Abbreviations: DCV, daclatasvir; DSV, dasabuvir; F2, fibrosis stage F2; HCV, hepatitis C virus; ICER, incremental cost-effectiveness ratio; LDV, ledipasvir; OBV, ombitasvir; PEG, pegylated-in-
terferon; PTV, paritaprevir; QALY, quality-adjusted life year; r, ritonavir; RBV, ribavirin; RNA, ribonucleic acid; SMV, simeprevir; SOF, sofosbuvir; SVR, sustained virologic response. 
(NOTE: All values are mean per-person values based on Monte-Carlo simulations of 1 000 000 individuals. Nondiscounted cost per 10 000 patients is calculated over 5 years. Cost-
effectiveness ratios may not match previous columns due to rounding.)
aDominated = strategies more costly and less effective than a competing strategy or strategies with an ICER greater than that of a more effective strategy.
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(between 0.2 and 0.3 QALYs) and is cost effective. If seeking 
rational cost control, payers should focus on price negotiations 
rather than treatment restrictions. At this time, with multiple 
interferon-free treatment options available, there are HCV 
treatment regimens that remain appealing to providers, but they 
are not cost effective. In treatment-naive, noncirrhotic patients 
with low viral load, for example, who are eligible for an 8-week 
course with sofosbuvir/ledipasvir, choosing a 12-week regimen 
in hope of gaining treatment efficacy is not cost effective. It will 
be possible to attain better population-level outcomes by nego-
tiating best prices and treating the greatest number possible, 
even if the preferred first-line regimen is somewhat less effec-
tive than another option.
Our work should be read in context of a growing body of 
literature. We independently confirm that (1) interferon-free 
options are cost effective [2–4] and that (2) treating early stage 
disease is preferred to F2+ only approaches [5, 6]. The analy-
sis extends those findings by determining the value of small 
improvements in efficacy in treatment-naive patients. We find 
that among competing regimens with efficacy >90%, cost should 
be the primary driver of formulary decisions. Negotiating prices 
and limiting formulary for noncirrhotic patients is a better 
approach to cost control than current disease stage treatment 
restrictions. To our knowledge, this paper provides one of the 
first quantitative comparisons of cost-control options.
This analysis has several limitations. First, our finding that 
F2+ only strategies are not preferred depends in part on assump-
tions about QoL with early stage HCV. Utility values are difficult 
to estimate and are imprecise. In sensitivity analyses, however, 
we identified the threshold utility value that results in treat F2+ 
only becoming preferred. We note that the threshold value 
(0.97) is substantially higher than base case (0.89) and higher 
Table 4. Cost-Effectiveness of Treatment for Hepatitis C Virus Infection Among Genotype 1a and 1b Cirrhotic Patients
Treatment Strategy Cost, $
Incremental 
Cost, $ QALYs
Incremental 
QALYs
ICER,  
$/QALY SVR, %
Nondiscounted Cost/10 
000 Patients, Billion $
Genotype 1a, Treatment-Naive
 No treatment 99 000 - 4.9 - - - 0.44
 PEG/RBV 48 weeks 158 000 59 600 7.0 2.1 Dominateda 23.5 0.91
 PEG/RBV/SMV 24 weeks 197 000 38 200 9.9 2.9 Dominateda 53.6 1.12
 PTV/r/OBV/DSV/RBV 12 weeks 245 000 146 000 13.7 8.9 16 500 92.7 1.36
 PEG/RBV/SOF 12 weeks 252 000 6900 12.3 −1.4 Dominateda 78.6 1.52
 SOF/LDV 12 weeks 255 000 10 000 14.0 0.2 43 000 95.1 1.45
 DCV/SOF 24 weeks 453 000 198 000 14.1 0.1 2 370 000 96.9 3.46
Genotype 1a, Treatment-Experienced
 No treatment 99 000 - 4.7 - - - 0.47
 PEG/RBV/SOF 12 weeks 246 000 147 000 11.5 6.8 Dominateda 78.3 1.54
 SOF/LDV/RBV 12 weeks 253 000 154 000 12.9 8.2 18 700 94.2 1.53
 PTV/r/OBV/DSV/RBV 24 weeks 315 000 62 100 12.8 −0.1 Dominateda 94.0 2.17
 SMV/SOF 12 weeks 317 000 64 500 12.5 −0.4 Dominateda 90.0 2.21
 SOF/LDV 24 weeks 334 000 81 000 13.0 0.2 520 000 96.8 2.34
 DCV/SOF/RBV 24 weeks 453 000 119 000 13.0 0.0 Dominateda 96.7 3.56
Genotype 1b, Treatment-Naive
 No treatment 99 000 - 4.9 - - - 0.44
 PEG/RBV 48 weeks 158 000 59 400 7.0 2.10 Dominateda 23.1 0.91
 PEG/RBV/SMV 24 weeks 205 000 46 800 10.8 3.80 Dominateda 62.4 1.15
 PTV/r/OBV/DSV/RBV 12 weeks 248 000 149 000 14.2 9.27 16 100 97.0 1.37
 PEG/RBV/SOF 12 weeks 252 000 4000 12.4 −1.79 Dominateda 78.5 1.52
 SOF/LDV 12 weeks 255 000 7100 14.0 −0.17 Dominateda 95.3 1.45
 DCV/SOF 24 weeks 453 000 205 000 14.1 −0.10 Dominateda 96.9 3.46
Genotype 1b, Treatment-Experienced
 No treatment 98 000 - 4.6 - - - 0.46
 PTV/r/OBV/DSV/RBV 12 weeks 239 000 141 000 13.0 8.40 16 800 96.3 1.38
 PEG/RBV/SOF 12 weeks 245 000 5800 11.4 −1.59 Dominateda 78.3 1.54
 SOF/LDV/RBV 12 weeks 252 000 12 600 12.8 −0.21 Dominateda 94.0 1.52
 SMV/SOF 12 weeks 319 000 79 700 13.1 0.10 828 000 97.4 2.19
 SOF/LDV 24 weeks 332 000 13 500 13.0 −0.16 Dominateda 96.4 2.34
 DCV/SOF/RBV 24 weeks 451 000 132 000 12.9 −0.18 Dominateda 96.2 3.56
Abbreviations: DCV, daclatasvir; DSV, dasabuvir; F2, fibrosis stage F2; HCV, hepatitis C virus; ICER, incremental cost-effectiveness ratio; LDV, ledipasvir; OBV, ombitasvir; PEG, pegylated-in-
terferon; PTV, paritaprevir; QALY, quality-adjusted life year; r, ritonavir; RBV, ribavirin; SMV, simeprevir; SOF, sofosbuvir; SVR, sustained virologic response. 
(NOTE: All values are mean per-person values based on Monte-Carlo simulations of 1 000 000 individuals. Nondiscounted cost per 10 000 patients is calculated over 5 years. Cost-
effectiveness ratios may not match previous columns due to rounding.)
aDominated = strategy is more costly and less effective than a competing strategy or strategies with an ICER greater than that of a more effective strategy.
Cost Effectiveness and Cost Containment in the Era of Interferon-Free Therapies to Treat HCV Genotype 1 • OFID • 9
than most reports in the literature [14]. Readers can use these 
results to calibrate conclusions with any emerging data about 
QoL. Second, similar to other cost-effectiveness analyses [2–4], 
our efficacy inputs are based on clinical trials and not real-world 
effectiveness. For instance, if twice-daily regimens are less effec-
tive than indicated in efficacy trials, whereas single tablet, once 
daily regimens are similar, then costly once daily regimens 
could appear to be economically attractive. However, our sen-
sitivity analyses demonstrate that among noncirrhotic patients, 
the gap in treatment effectiveness would need to be large to jus-
tify the substantially higher price: for example, a large gap of 
5% better effectiveness would only support $4000 in increased 
price. In addition, we also use the clinical trials to inform model 
demographics, which may be different from the general HCV 
population, although our conclusions do not change in our sen-
sitivity analyses varying age, mortality, and QoL (all of which 
may differ with demographics) (Supplemental Tables 4, 5, 13, 
14). Third, because knowledge of the optimal combination of 
available medications to treat HCV is evolving, this analysis 
excludes treatment regimens recently approved. For instance, 
we did not include recommended regimes of elbasvir/grazo-
previr or sofosbuvir/velpatasvir [42]; however, this approach is 
unlikely to be significantly different from other highly effica-
cious regiments. Likewise, our analysis was completed shortly 
before the US Food and Drug Administration issued a “black 
box warning” about the use of paritaprevir/ritonavir/ombi-
tasvir/dasabuvir in patients with advanced liver disease [43]. 
Nevertheless, we demonstrate that tradeoffs between price and 
efficacy will be relevant to considering the cost effectiveness of 
these future regimens compared with the current standard of 
care. Fourth, because discounts negotiated with pharmaceuti-
cal companies typically include a nondisclosure agreement, it 
is not possible to know what each payer pays for HCV medi-
cations. In the base case, we assumed an average discount of 
23% off of AWP, and we explored that cost in extensive sensi-
tivity analysis (Supplemental Tables 11–12). Fifth, although we 
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Figure 1. Cost-effectiveness acceptability curves for the treatment of hepatitis C 
virus (HCV) genotype 1b patients with and without cirrhosis. Each panel presents 
the results of probabilistic sensitivity analyses in which we performed multiple 
iterations of the cost-effectiveness simulation, each time drawing treatment effi-
cacy parameters from defined probability density functions. The horizontal axis 
represents increasing societal willingness to pay thresholds. Each line represents a 
treatment strategy. For clarity, we excluded those strategies where the incremental 
cost-effectiveness ratio (ICER) was above a willingness-to-pay (WTP) threshold of 
$500 000 in >99% of iterations. The vertical axis depicts the percentage of the 
simulation iterations in which a given strategy was “preferred” from a cost-effec-
tiveness perspective at a given societal willingness to pay. All costs are in 2014 US 
dollars and discounted at an annual rate of 3%. DCV, daclatasvir; DSV, dasabuvir; 
LDV, ledipasvir; OBV, ombitasvir; PTV, paritaprevir; QALY, quality-adjusted life year; 
r, ritonavir; RBV, ribavirin; SMV, simeprevir; SOF, sofosbuvir. 
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Figure 2. Two-way sensitivity analysis on interferon-free regimen efficacy and cost. 
The analysis holds the efficacy and cost of 1 interferon-free treatment (“regimen A”) 
constant, while varying the efficacy and cost of a competing interferon-free regimen 
(“regimen B”). To improve generalizability such that the analysis applies to future 
interferon-free treatment options, we defined the ranges of drug cost and efficacy 
based on those of current competing drugs, but the analysis is not based on a single 
regimen. The horizontal axis depicts the relative efficacy of regimen B compared with 
regimen A. The vertical axis depicts the relative cost. Each line depicts the threshold 
cost that results in regimen B having an incremental cost-effectiveness ratio (ICER) 
<$100 000/quality-adjusted life year compared with regimen A at the given relative 
efficacy. The slope of the line thus represents the economic value of an additional 
percentage point increase in treatment efficacy. The solid line represents cirrhotic 
patients, and the dotted line represents noncirrhotic patients. All costs are in 2014 
US dollars and discounted at an annual rate of 3%. SVR, sustained virologic response.
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account for increased costs and mortality and decreased utility 
of advancing liver disease, we did not model specific manifesta-
tions of this such as hepatocellular carcinoma, liver transplan-
tation, or other extrahepatic consequences of HCV. Modeling 
these effects separately would not change our overall results, but 
it may be beneficial for stakeholders who want to find another 
way to quantify the effect of treatment on health outcomes. 
Sixth, although we assumed that fibrosis progression halts after 
SVR, some studies suggest that progression may continue at a 
much slower rate or that fibrosis would regress instead. In sen-
sitivity analysis where patients were subject to lower QoL after 
SVR (if progression continued, for example), our conclusions 
were unchanged, although the ICERs increased. The effect 
of fibrosis regression is not well understood in the literature, 
although if present we would expect treatment to become more 
attractive and for ICERs to fall given the additional benefit of 
regression. In addition, our model assumed a linear progression 
through fibrosis stages with a 25-year median time to cirrhosis 
among the cohort. More recent literature suggests that fibrosis 
progression is not linear, with faster progression through early 
stages of disease [44]. However, the main driver of cost-effec-
tiveness conclusions in the model was the time to becoming 
cirrhotic. We experimented with a broad array of median times 
to cirrhosis, and we found that our conclusions are consistent. 
Seventh, our analysis assumed a healthcare system perspective 
that included the costs of medical care (HCV and non-HCV), 
but it did not include costs related to lost labor productivity and 
disability. Were we to incorporate those costs in the model, the 
net cost of HCV therapy would be less, although it is difficult 
to imagine a scenario in which preventing disability provides 
so much benefit as to entirely offset the high cost of treatment. 
Finally, we assumed that competing risks of death for HCV-
infected patients initiating therapy are similar to those of the 
general US population. If history of substance use or other risk 
factors that led to HCV infection also have an impact on long-
term mortality, then the cost-effectiveness ratios of treatment 
may be higher than those reported.
CONCLUSIONS
New therapies to treat HCV GT1 have changed the paradigm of 
HCV care from chronic, moderately effective disease manage-
ment to short-term, curative therapy [45]. Our analysis demon-
strates that expanding treatment access, including to patients 
with early stage disease, will improve clinical outcomes and is 
cost effective, but it will have a very high cost. Currently, many 
payers restrict access to HCV therapy based on fibrosis stage [9, 
46], and although some have been forced to relax restrictions 
through litigation [47], these policy changes are occurring with-
out clear evidence of the right cost-control measures and with-
out knowledge of the long-term consequences of these policies 
on human health and local budgets. We show that such strat-
egies are not the best approach to control spending on HCV 
treatment from the perspective of the health system. We also 
find that lower drug costs for interferon-free regimens to treat 
noncirrhotic patients in a competitive drug market will improve 
cost effectiveness and reduce short-term payer costs, suggesting 
that payers should focus on price negotiations as a cost-control 
strategy. Now that there are multiple effective HCV regimens 
and there is greater competition in this market, it is important 
to expand efforts to identify and treat patients with chronic 
HCV infection in the United States.
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